COVID Vaccine-Associated Uveitis

ABSTRACT

Purpose

Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed.

Methods

A literature review of uveitis post various SARS-CoV-2 vaccinations.

Results

Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt–Koyanagi–Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases.

Conclusion

Uveitis following Covid vaccinations is uncommon and has a good prognosis.

KEYWORDS:

• COVID vaccination
• mRNA COVID vaccine
• SARS-Cov-2 vaccines
• uveitis
• SARS-Cov-2 vaccine-associated uveitis

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.